|MiSeq System||Samples per run (by reagent kit version): v2: 4, v3: 8 (based on 150x mean coverage of targeted content)||Up to 2 × 150 bp|
|NextSeq 550 System||Samples per run: mid output: 48, high output: 96 (based on 150x mean coverage of targeted content)||Up to 2 × 150 bp|
|TruSight Inherited Disease||TruSight One Sequencing Panels||TruSight Cardio Sequencing Kit|
|Content Specifications||2.25 Mb genomic content (552 genes)||TruSight One: ~12 Mb genomic content (~4800 genes).
TruSight One Expanded: ~16.5 Mb genomic content (~6700 genes).
|575 Kb genomic content (174 genes)|
|Description||Fixed research panel focused on severe pediatric onset disorders.||Fixed research panels targeting exonic regions that harbor disease-causing variants.||Targeted sequencing research panel to identify causal variants associated with 17 inherited cardiac conditions.|
|Input Quantity||50 ng DNA||50 ng DNA||50 ng DNA|
|Method||Target Enrichment , Targeted DNA Sequencing||Target Enrichment , Targeted DNA Sequencing||Target Enrichment , Targeted DNA Sequencing|
|Multiplexing||Up to 96-plex||Up to 96-plex||Up to 96-plex|
|Specialized Sample Types||Not FFPE-Compatible||Not FFPE-Compatible||Not FFPE-Compatible|
Coverage uniformity is given for 6 samples with respect to the percentage of targeted regions at varying mean normalized read depths. The 6 samples were prepared and then enriched using the TruSight Rapid Capture Kit along with the TruSight Inherited Disease sequencing panel. Over 95% of bases (> 2.0 Mb) were covered at 0.2x mean coverage for each sample.
Note regarding biomarker patents and other patents unique to specific uses of products:
Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.